

## Appendix 2: Classifications of commoner drugs used to prevent liver rejection

\*indicates not specifically licensed in UK for use in liver transplantation

MODE OF ACTION	NAME
<b>Depletion of lymphocytes</b>	Polyclonal antibodies: ALG, thymoglobulin Monoclonal antibodies: OKT3, Alemtuzumab*
<b>Inhibition of lymphocyte activation</b>	Antibodies: IL2R antibodies: Basiliximab, Daclizumab Anti CD80/86 antibodies: Belatacept*
<b>Corticosteroids*</b>	Prednisolone, methylprednisolone
<b>Immunophilin-binding drugs</b>	Calcineurin inhibitors (CNI): Cyclosporin and tacrolimus mTOR Inhibitors: Sirolimus*, Everolimus
<b>Inhibition of de novo nucleotide synthesis</b>	Purine synthesis inhibitors (IMPDH): mycophenolate Pyrimidine synthesis inhibitors (DHODH): Leflunomide*
<b>Anti-metabolites:</b>	Azathioprine, cyclophosphamide*
<b>Inhibitors of lymphocyte trafficking and interaction</b>	Fingolimod* Antibodies to ICAM-1

ALG: anti-lymphocyte globulin; TOR: target of rapamycin; IMPDH: inosine monophosphate dehydrogenase; DHODH: Dihydroorotate dehydrogenase  
IL2R: interleukin-2 receptor; ICAM: intercellular adhesion molecule